PHA/IL-2-treated primary human CD4+ T cells exposed to this recombinant reporter virus reached 1.1, 5.8 and 6.6% of HSA-positive cells after 24, 48 and 72 h post-infection, respectively (Figure 1B, left panels). The gene discussed is CD4; the disease is infection.